ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
ADMA Biologics, a specialty plasma-derived therapeutics company, has become a closely watched earnings story as its flagship immune globulin product, ASCENIV, has steadily gained physician adoption. This third quarter report matters because it tests whether the company can sustain its profitability trajectory while navigating a competitive standard immune globulin (IG) market that has pressured its legacy BIVIGAM product. For investors, the key question is whether accelerating ASCENIV demand and expanding gross margins can offset BIVIGAM headwinds and continue translating into earnings growth. With the stock trading well below its 52-week highs, the print also carried outsized weight as a signal on the durability of ADMA's commercial momentum and margin expansion.
For the third quarter ended September 30, 2026, ADMA Biologics reported total revenue of $141.1 million, a 5% increase from $134.2 million a year earlier and a 13% sequential gain from $124.4 million. Revenue topped the consensus estimate of roughly $138.1 million.
ASCENIV, the company's immune globulin therapy for primary immunodeficiency, generated $124.7 million in revenue, up 31% year-over-year and 21% sequentially. In contrast, BIVIGAM revenue fell to $15.4 million from $23.8 million in the prior-year quarter, reflecting ongoing competitive and inventory pressures in the standard IG market.
Gross profit rose to $99.9 million, with gross margin expanding to 71% from 56% a year ago. GAAP (Generally Accepted Accounting Principles) net income reached $49.9 million, up 37% year-over-year, with GAAP basic EPS of $0.22 versus $0.15 a year earlier. Adjusted EPS of $0.23 beat the $0.20 consensus by $0.03, while adjusted EBITDA climbed 32% year-over-year to $77.3 million.
Management also raised its full-year 2026 outlook, now guiding to at least $180 million in adjusted net income and at least $275 million in adjusted EBITDA, while maintaining its minimum revenue target of $530 million.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for earnings-focused research. Explore the AI Screener to build a watchlist tailored to your own criteria.
ADMA entered the report with cautious sentiment, having missed revenue estimates in the prior quarter and trading down roughly 32% over the trailing 12 months. The third quarter beat on both the top and bottom lines, driven by ASCENIV's 31% growth and a raised full-year profit outlook, provided a positive counterpoint. Adjusted EPS of $0.23 against a $0.20 consensus and the upward revision to adjusted net income and EBITDA guidance were the primary drivers of the market's interpretation. Investors appeared to weigh the strength of ASCENIV momentum and margin expansion against lingering BIVIGAM weakness and elevated inventory and debt levels on the balance sheet.
Looking ahead, the central question is whether ASCENIV can sustain its double-digit growth trajectory. Management indicated that favorable demand trends have continued into the fourth quarter, supported by expanding physician adoption and new patient starts. Upcoming clinical data, including an analysis of real-world outcomes in primary immunodeficiency patients scheduled for presentation at a major allergy and immunology conference, could further reinforce ASCENIV's differentiation.
At the same time, investors should monitor the standard IG market closely. Persistent competitive pricing and distribution channel inventory pressures have weighed on BIVIGAM, and any further deterioration would partially offset ASCENIV's gains. Margin durability will depend on product mix and continued benefits from the company's yield-enhanced manufacturing process.
Other factors to watch include SG-001, the company's pneumococcal hyperimmune globulin development candidate, and the trajectory of research and development spending, as well as balance sheet trends such as inventory, accounts receivable, and long-term debt. The company's share repurchase activity also remains a consideration for per-share results. As always, upcoming quarterly results will be evaluated against the company's own guidance and consensus expectations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology